share_log

Mangoceuticals | 10-Q: Q3 2024 Earnings Report

Mangoceuticals | 10-Q: Q3 2024 Earnings Report

Mangoceuticals | 10-Q:2024财年三季报
美股SEC公告 ·  11/14 16:25

Moomoo AI 已提取核心信息

Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end...Show More
Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end of the previous year. Mangoceuticals also reported a working deficit of $1.3 million and an accumulated deficit of $17,985,966 as of September 30, 2024. The company highlighted the need for additional funding to support operations over the next 12 months and may seek additional funding through equity or debt financings. Mangoceuticals also mentioned a strategic review process to evaluate potential transactions that could result in a change of control or a significant change in operations.
Mangoceuticals 公司报告了截至2024年9月30日的季度财务业绩。本季度的营业收入为$133,368,较前一年同期的$245,160有所减少。营业费用总计$1,840,745,略低于前一年同期的$1,944,049。公司净损失为$1,999,694,而去年同季度的净损失为$1,799,460。营业收入和净损失的减少归因于由于迁移至新的远程医疗平台而导致营销活动延迟。截至2024年9月30日为止的九个月,公司的净损失为$6,758,630,营业收入为$510,626,较去年同期的$487,119有所增加。公司的现金及现金等价物为$73,912,低于上一年底的$739,006。Man...展开全部
Mangoceuticals 公司报告了截至2024年9月30日的季度财务业绩。本季度的营业收入为$133,368,较前一年同期的$245,160有所减少。营业费用总计$1,840,745,略低于前一年同期的$1,944,049。公司净损失为$1,999,694,而去年同季度的净损失为$1,799,460。营业收入和净损失的减少归因于由于迁移至新的远程医疗平台而导致营销活动延迟。截至2024年9月30日为止的九个月,公司的净损失为$6,758,630,营业收入为$510,626,较去年同期的$487,119有所增加。公司的现金及现金等价物为$73,912,低于上一年底的$739,006。Mangoceuticals 还报告了 $130万 的工作透支和截至2024年9月30日的累积透支为 $17,985,966。公司强调了需要额外资金支持未来12个月的运营,并可能通过股权或债务融资寻求额外资金。Mangoceuticals 还提及了一项战略审查流程,以评估可能导致控制权变更或运营方式显著变化的潜在交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息